RecruitingNon-Alcoholic Fatty Liver DiseaseType 2 DiabetesMitochondrial Metabolism Disorders
Quantifying Hepatic Mitochondrial Fluxes in Humans
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
Sponsor: The University of Texas Health Science Center at San Antonio
You may qualify if…
- ✓ Confirmed T2D based on OGTT (2 h glucose ≥200 mg/dl).
- ✓ Treated with diet, metformin, and/or sulfonylurea and in good general health determined by medical history, physical exam, and routine blood chemistries;
- ✓ age = 18-80 years;
- ✓ BMI = 25-40 kg/m2;
- ✓ HbA1c = 7-10%; stable body weight (±4 pounds) over the preceding 3-months;
- ✓ not taking any medication known to affect glucose metabolism other than antidiabetic medications.
- ✓ Evidence of moderate/severe fatty liver (steatosis; grade S2/S3 on FibroScan corresponding to ≥10% fat on MRI-PDFF) and no/minimal hepatic fibrosis (grade F0/F1 on FibroScan).
- ✓ Confirmed T2D based on OGTT (2 h glucose ≥200 mg/dl).
You may not qualify if…
- ✕ Alcohol consumption \>14 units/week for women and \>21 units/week for men.
- ✕ Liver cirrhosis (fibrosis stage 4).
- ✕ Evidence of other forms of chronic liver disease, including alcoholic liver disease, hepatitis B and C, primary biliary cholangitis, suspected/proven liver cancer and any other liver disease other than NAFLD.
- ✕ Type 1 diabetes and/or GAD positive subjects.
- ✕ Subjects not drug naive or have been on metformin more than 3 months.
- ✕ Presence of proliferative retinopathy.
- ✕ Urine albumin excretion \> 300 mg/day.
- ✕ History of NY Class III-IV heart failure
Where it's recruiting
Texas
San Antonio
Source: ClinicalTrials.gov · NCT05305287 · last updated 2026-08-17